Amboy Street Ventures Joins Granata Bio’s $14M Series A

Amboy Street Ventures (ASV) is excited to announce its latest investment in Granata Bio.

Amboy Street Ventures is excited to announce its latest investment in Granata Bio, a biopharma company improving the In Vitro Fertilization (IVF) medication market. We invested in Granata Bio's $14M Series A round that was led by GV (Google Ventures) with participation from other strategic investors including Cooper Surgical and Gedeon Richter. 

The demand for IVF has been steadily increasing due to shifting family planning trends, reduced stigma surrounding infertility,  and improved success rates. This rise reflects IVF's essential role in helping individuals and couples overcome fertility challenges and realize their parenthood aspirations.

Yet the price of IVF remains a barrier. One IVF cycle, encompassing ovarian stimulation, egg retrieval, and embryo transfer, can fluctuate between $15,000 and $30,000. This cost is contingent on the choice of the fertility clinic and the medications needed. The medications alone can contribute to as much as 35% of the overall cost. 

A small group of pharmaceutical companies have a monopoly over the IVF medication market leading to little innovation and consistent inflation of prices. Granata Bio is developing a suite of IVF medications to disrupt and diversify the stagnant market. Granata Bio’s growing portfolio can be found here.  

Evan Sussman, CEO of Granata Bio, and the remaining leadership team have more than 75 years of combined experience in fertility, specifically in clinical development, regulatory strategy, and commercialization of IVF drugs. With this raise, Granata Bio will accelerate their fertility biopharma pipeline to invigorate the $3.6B global infertility medication market.

“Granata is taking a novel approach to both address current market dynamics and to develop unique products targeting unmet needs in women’s health,” says CEO Evan Sussman. “This funding is an exciting next step toward our mission of creating access for fertility patients with new therapeutic solutions.”

"IVF is necessary in so many journeys to parenthood. We are thrilled to team up with Granata Bio as it disrupts the stagnant IVF medication market and makes IVF more accessible, comfortable, and effective." - Carli Sapir, Partner at Amboy Street Ventures

Granata Bio is the latest to join ASV’s growing portfolio of brands pioneering solutions in women’s health and sexual health alongside Contraline, the maker of male birth control, Hey Jane, leading telehealth abortion and women’s intimate healthcare provider, and Testmate, the maker of rapid, at-home STD tests. See the full portfolio here.

Continue Reading

ASV Insights – Top 10 Deals of 2023: $425M Acquisition of Menopause CPG Company

This week we explore the acquisition of Bonafide Health, a significant deal in the Menopause space. This strategic move marks a pivotal shift, bringing much-needed attention to an often overlooked area of women’s health.

Top 10 Deals of 2023: Imaware Acquires Binx Health’s STI Testing Business

This week we assess the acquisition of Binx Health, an at-home STI testing company and consider similar pioneers in the sexual health space.

Dame Settles with the MTA in landmark advertising win for women’s sexual health

The Brooklyn-based startup will become the first female-founded pleasure product brand to be approved to advertise throughout the city’s public transportation.

ASV Insights – Top 10 Deals of 2023: $425M Acquisition of Menopause CPG Company

This week we explore the acquisition of Bonafide Health, a significant deal in the Menopause space. This strategic move marks a pivotal shift, bringing much-needed attention to an often overlooked area of women’s health.

Top 10 Deals of 2023: Imaware Acquires Binx Health’s STI Testing Business

This week we assess the acquisition of Binx Health, an at-home STI testing company and consider similar pioneers in the sexual health space.

Fast track our industry.
Get in touch today.